ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO941

The Effectiveness of mRNA COVID-19 Vaccine Against SARS-CoV-2 Infection in Hemodialysis Patients: A Case-Control Study

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Hamad, Abdullah Ibrahim, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Elshirbeny, Mostafa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ali, Mohamed Yousif Mohamed Salih, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ghonimi, Tarek Abdellatif, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ibrahim, Rania Abdelaziz, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Yasin, Fadumo Yusuf, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Singh, Poonam Ravinder, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Aly, Sahar, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Abuhelaiqa, Essa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Al-Malki, Hassan A., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Alkadi, Mohamad M., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
Background

Hemodialysis (HD) patients are at higher risk for SARS-CoV-2 infection and its severe complications compared to the general population. Several studies examined the effectiveness of COVID-19 vaccines in this highly vulnerable population but showed mixed results. The aim of this study was to determine the effectiveness of mRNA vaccines against confirmed SARS-CoV-2 infection in HD patients in the State of Qatar.

Methods

We used a test-negative case-control design to determine the effectiveness of vaccination in HD patients > 14 days after the second dose. Ninety-five patients had positive SARS-CoV-2 PCR (cases), while 884 patients had negative PCR (controls). Vaccine effectiveness was determined using the following formula [Vaccine effectiveness = 1 – Odds (T+ |vaccinated) /Odds (T+|non-vaccinated)].

Results

Thirty out of 691 vaccinated HD patients had positive SARS-CoV-2 PCR versus 65 out of 288 non-vaccinated patients (4% vs. 23%, P<0.0001). Patients were more likely to have positive PCR if they were females (P<0.0001), elderly (P=0.02), or Asians (P=0.03). The overall effectiveness of mRNA COVID-19 vaccines against confirmed SARS-CoV-2 infection was 84.5% (95% CI: 76.5-89.8; Table 1)

Conclusion

Our data support the importance of using the mRNA COVID-19 vaccine in HD patients to prevent SARS-CoV-2 infection in such a high-risk population.

Table 1: Vaccine Effectiveness against confirmed infection
Vaccine typePositive SARS-CoV-2 Negative SARS-CoV-2 Adjusted vaccine effectiveness, %(95% CI)
mRNA-1273 (Moderna)16894.9(79.7 to 99.8)
BNT-162b2 (Pfizer)2959383.3(74.4 to 89.1)
All vaccinated 3066184.5(76.5 to 89.8)
Non-vaccinated65223ReferenceReference